The forecast for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) medicine sales in Germany indicates a steady decline from 2024 to 2028, with values dropping from 737.3 million USD to 644.4 million USD PPP. From 2024 to 2025, the year-on-year decrease is 3.2%, followed by 3.3% annually until 2028. These consistent declines suggest a significant overall trend reflecting a 5-year CAGR of 3.32% on average.
Future trends to observe include potential impact from advancements in medical treatments that might reduce GORD prevalence or shifts in healthcare policies in Germany. Possible emerging markets or disruptive pharmaceuticals could also influence the future landscape.
